178 related articles for article (PubMed ID: 33904236)
21. Turning double hydrophilic into amphiphilic: IR825-conjugated polymeric nanomicelles for near-infrared fluorescence imaging-guided photothermal cancer therapy.
Pan GY; Jia HR; Zhu YX; Wu FG
Nanoscale; 2018 Jan; 10(4):2115-2127. PubMed ID: 29326993
[TBL] [Abstract][Full Text] [Related]
22. Aptamer-functionalized albumin-based nanoparticles for targeted drug delivery.
Xu L; He XY; Liu BY; Xu C; Ai SL; Zhuo RX; Cheng SX
Colloids Surf B Biointerfaces; 2018 Nov; 171():24-30. PubMed ID: 30005287
[TBL] [Abstract][Full Text] [Related]
23. Enhanced targeting of 3D pancreatic cancer spheroids by aptamer-conjugated polymeric micelles with deep tumor penetration.
Tian L; Pei R; Zhong L; Ji Y; Zhou D; Zhou S
Eur J Pharmacol; 2021 Mar; 894():173814. PubMed ID: 33352182
[TBL] [Abstract][Full Text] [Related]
24. Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona.
Li Z; Han X; Zhai Y; Lian H; Zhang D; Zhang W; Wang Y; He Z; Liu Z; Sun J
Colloids Surf B Biointerfaces; 2015 Jun; 130():133-40. PubMed ID: 25907597
[TBL] [Abstract][Full Text] [Related]
25. Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy.
Li X; Li Z; Yu H
Chem Commun (Camb); 2020 Dec; 56(93):14653-14656. PubMed ID: 33155587
[TBL] [Abstract][Full Text] [Related]
26. The development and testing of aptamers for cancer.
Barbas AS; White RR
Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
[TBL] [Abstract][Full Text] [Related]
27. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
28. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
29. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
[TBL] [Abstract][Full Text] [Related]
30. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
31. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics.
Zhu G; Zheng J; Song E; Donovan M; Zhang K; Liu C; Tan W
Proc Natl Acad Sci U S A; 2013 May; 110(20):7998-8003. PubMed ID: 23630258
[TBL] [Abstract][Full Text] [Related]
32. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
33. Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.
Vandghanooni S; Eskandani M; Barar J; Omidi Y
J Mol Med (Berl); 2018 Sep; 96(9):885-902. PubMed ID: 30056527
[TBL] [Abstract][Full Text] [Related]
34. Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer.
Ma W; Yang Y; Liu Z; Zhao R; Wan Q; Chen X; Tang B; Zhou Y; Lin Y
ACS Appl Mater Interfaces; 2023 Sep; 15(37):43359-43373. PubMed ID: 37670592
[TBL] [Abstract][Full Text] [Related]
35. Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy.
Jurek PM; Zabłocki K; Waśko U; Mazurek MP; Otlewski J; Jeleń F
Int J Nanomedicine; 2017; 12():2941-2950. PubMed ID: 28442904
[TBL] [Abstract][Full Text] [Related]
36. Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.
Fu Z; Xiang J
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266216
[TBL] [Abstract][Full Text] [Related]
37. Polyphenol-Based Nanomedicine Evokes Immune Activation for Combination Cancer Treatment.
Zhang Z; Sang W; Xie L; Li W; Li B; Li J; Tian H; Yuan Z; Zhao Q; Dai Y
Angew Chem Int Ed Engl; 2021 Jan; 60(4):1967-1975. PubMed ID: 33078525
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint blockade: a common denominator approach to cancer therapy.
Topalian SL; Drake CG; Pardoll DM
Cancer Cell; 2015 Apr; 27(4):450-61. PubMed ID: 25858804
[TBL] [Abstract][Full Text] [Related]
39. Nanoantagonists with nanophase-segregated surfaces for improved cancer immunotherapy.
Ma Y; Qiao SL; Wang Y; Lin YX; An HW; Wu XC; Wang L; Wang H
Biomaterials; 2018 Feb; 156():248-257. PubMed ID: 29216535
[TBL] [Abstract][Full Text] [Related]
40. Aptamer-Targeted Attenuation of IL-2 Signaling in CD8
Rajagopalan A; Berezhnoy A; Schrand B; Puplampu-Dove Y; Gilboa E
Mol Ther; 2017 Jan; 25(1):54-61. PubMed ID: 28129128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
